Depot-based delivery systems for pro-angiogenic peptides: A review

Frontiers in Bioengineering and Biotechnology

Volumn 3, Issue JUL, 2015, Pages

  Van Hove, Amy H ^a   Benoit, Danielle S W ^a,b  

^a University of Rochester   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Biomaterials; Controlled release; Depot based; Drug delivery; Hydrogels; Review

Indexed keywords

EID: 84962649411     PISSN: None     EISSN: 22964185     Source Type: Journal    
DOI: 10.3389/fbioe.2015.00102     Document Type: Review

References (179)

1. Aachmann, F. L., Larsen, K. L., and Wimmer, R. (2012). Interactions of cyclodextrins with aromatic amino acids: a basis for protein interactions. J. Incl. Phenom. Macrocycl. Chem. 73, 349-357. doi:10.1007/s10847-011-0071-y
2. Adams, R. H., and Alitalo, K. (2007). Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell Biol. 8, 464-478. doi:10.1038/nrm2183
3. Agu, R. U., Ugwoke, M. I., Armand, M., Kinget, R., and Verbeke, N. (2001). The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res. 2, 198-209. doi:10.1186/rr58
4. Ahmed, T. A. E., Griffith, M., and Hincke, M. (2007). Characterization and inhibition of fibrin hydrogel-degrading enzymes during development of tissue engineering scaffolds. Tissue Eng. 13, 1469-1477. doi:10.1089/ten.2006.0354
5. Akeson, A. L., Woods, C. W., Hsieh, L. C., Bohnke, R. A., Ackermann, B. L., Chan, K. Y., et al. (1996). AF12198, a novel low molecular weight antagonist, selectively binds the human type I interleukin (IL)-1 receptor and blocks in vivo responses to IL-1. J. Biol. Chem. 271, 30517-30523. doi:10.1074/jbc.271.48.30517
6. Al-Hilal, T. A., Alam, F., and Byun, Y. (2013). Oral drug delivery systems using chemical conjugates or physical complexes. Adv. Drug Deliv. Rev. 65, 845-864. doi:10.1016/j.addr.2012.11.002
7. Anseth, K. S., Metters, A. T., Bryant, S. J., Martens, P. J., Elisseeff, J. H., and Bowman, C. N. (2002). In situ forming degradable networks and their application in tissue engineering and drug delivery. J. Control. Release 78, 199-209. doi:10.1016/S0168-3659(01)00500-4
8. Antosova, Z., Mackova, M., Kral, V., and Macek, T. (2009). Therapeutic application of peptides and proteins: parenteral forever? Trends Biotechnol. 27, 628-635. doi:10.1016/j.tibtech.2009.07.009
9. Atala, A. (2004). Tissue engineering and regenerative medicine: concepts for clinical application. Rejuvenation Res. 7, 15-31. doi:10.1089/154916804323105053
10. Atala, A., Bauer, S. B., Soker, S., Yoo, J. J., and Retik, A. B. (2006). Tissue-engineered autologous bladders for patients needing cystoplasty. Lancet 367, 1241-1246. doi:10.1016/S0140-6736(06)68438-9
11. Bader, R. A., and Putnam, D. A. (2014). Engineering Polymer Systems for Improved Drug Delivery. Hoboken, NJ: John Wiley & Sons, Inc.
12. Benoit, D. S. W., and Anseth, K. S. (2005). Heparin functionalized PEG gels that modulate protein adsorption for hMSC adhesion and differentiation. Acta Biomater. 1, 461-470. doi:10.1016/j.actbio.2005.03.002
13. Benoit, D. S. W., Durney, A. R., and Anseth, K. S. (2007). The effect of heparin-functionalized PEG hydrogels on three-dimensional human mesenchymal stem cell osteogenic differentiation. Biomaterials 28, 66-77. doi:10.1016/j.biomaterials.2006.08.033
14. Ben-Sasson, S. A., Licht, T., Tsirulnikov, L., Reuveni, H., and Yarnitzky, T. (2003). Induction of pro-angiogenic signaling by a synthetic peptide derived from the second intracellular loop of S1P(3) (EDG3). Blood 102, 2099-2107. doi:10.1182/blood-2002-12-3634
15. Bouhadir, K. H., Lee, K. Y., Alsberg, E., Damm, K. L., Anderson, K. W., and Mooney, D. J. (2001). Degradation of partially oxidized alginate and its potential application for tissue engineering. Biotechnol. Prog. 17, 945-950. doi:10.1021/bp010070p
16. Brem, H., and Tomic-Canic, M. (2007). Cellular and molecular basis of wound healing in diabetes. J. Clin. Invest. 117, 1219-1222. doi:10.1172/JCI32169
17. Brudno, Y., Ennett-Shepard, A. B., Chen, R. R., Aizenberg, M., and Mooney, D. J. (2013). Enhancing microvascular formation and vessel maturation through temporal control over multiple pro-angiogenic and pro-maturation factors. Biomaterials 34, 9201-9209. doi:10.1016/j.biomaterials.2013.08.007
18. Cai, S. S., Liu, Y. C., Shu, X. Z., and Prestwich, G. D. (2005). Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor. Biomaterials 26, 6054-6067. doi:10.1016/j.biomaterials.2005.03.012
19. Carmeliet, P., and Jain, R. K. (2000). Angiogenesis in cancer and other diseases. Nature 407, 249-257. doi:10.1038/35025220
20. Castronuovo, G., Elia, V., Fessas, D., Giordano, A., and Velleca, F. (1995). Thermodynamics of the interaction of cyclodextrins with aromatic and alpha, omega-amino acids in aqueous-solutions-a calorimetric study at 25-degrees-C. Carbohydr. Res. 272, 31-39. doi:10.1016/0008-6215(95)00000-J
21. Cebix. (2013). A Phase 2b, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of CBX129801 (Ersatta™), Long-Acting Synthetic C-Peptide, in Type 1 Diabetes Mellitus Subjects. ClinicalTrials.gov Identifier: NCT01681290.
22. Chen, Q. Z., Harding, S. E., Ali, N. N., Lyon, A. R., and Boccaccini, A. R. (2008). Biomaterials in cardiac tissue engineering: ten years of research survey. Mater. Sci. Eng. R Rep. 59, 1-37. doi:10.1016/j.mser.2007.08.001
23. Chu, H., and Wang, Y. (2012). Therapeutic angiogenesis: controlled delivery of angiogenic factors. Ther. Deliv. 3, 693-714. doi:10.4155/tde.12.50
24. Cianfrocca, M. E., Kimmel, K. A., Gallo, J., Cardoso, T., Brown, M. M., Hudes, G., et al. (2006). Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours. Br. J. Cancer 94, 1621-1626. doi:10.1038/sj.bjc.6603171
25. Copolovici, D. M., Langel, K., Eriste, E., and Langel, U. (2014). Cell-penetrating peptides: design, synthesis, and applications. ACS Nano 8, 1972-1994. doi:10.1021/nn4057269
26. Craik, D. J., Fairlie, D. P., Liras, S., and Price, D. (2013). The future of peptide-based drugs. Chem. Biol. Drug Des. 81, 136-147. doi:10.1111/cbdd.12055
27. D'Andrea, L. D., Iaccarino, G., Fattorusso, R., Sorriento, D., Carannante, C., Capasso, D., et al. (2005). Targeting angiogenesis: structural characterization and biological properties of a de novo engineered VEGF mimicking peptide. Proc. Natl. Acad. Sci. U.S.A. 102, 14215-14220. doi:10.1073/pnas.0505047102
28. Demidova-Rice, T. N., Geevarghese, A., and Herman, I. M. (2011). Bioactive peptides derived from vascular endothelial cell extracellular matrices promote microvascular morphogenesis and wound healing in vitro. Wound Repair Regen. 19, 59-70. doi:10.1111/j.1524-475X.2010.00642.x
29. Demidova-Rice, T. N., Wolf, L., Deckenback, J., Hamblin, M. R., and Herman, I. M. (2012). Human platelet-rich plasma-and extracellular matrix-derived peptides promote impaired cutaneous wound healing in vivo. PLoS ONE 7:e32146. doi:10.1371/journal.pone.0032146
30. Derma Sciences, I. (2015). Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers (STRIDE 1). ClinicalTrials.gov Identifier: NCT01830348.
31. Diana, D., Ziaco, B., Colombo, G., Scarabelli, G., Romanelli, A., Fedone, C., et al. (2008). Structural determinants of the unusual helix stability of a de novo engineered vascular endothelial growth factor (VEGF) mimicking peptide. Chemistry 14, 4164-4166. doi:10.1002/chem.200800180
32. Du, A. W., and Stenzel, M. H. (2014). Drug carriers for the delivery of therapeutic peptides. Biomacromolecules 15, 1097-1114. doi:10.1021/bm500169p
33. Ehrbar, M., Djonov, V. G., Schnell, C., Tschanz, S. A., Martiny-Baron, G., Schenk, U., et al. (2004). Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth. Circ. Res. 94, 1124-1132. doi:10.1161/01.RES.0000126411.29641.08
34. Ehrbar, M., Metters, A., Zammaretti, P., Hubbell, J. A., and Zisch, A. H. (2005). Endothelial cell proliferation and progenitor maturation by fibrin-bound VEGF variants with differential susceptibilities to local cellular activity. J. Control. Release 101, 93-109. doi:10.1016/j.jconrel.2004.07.018
35. Fairbanks, B. D., Schwartz, M. P., Halevi, A. E., Nuttelman, C. R., Bowman, C. N., and Anseth, K. S. (2009). A versatile synthetic extracellular matrix mimic via thiol-norbornene photopolymerization. Adv. Mater. Weinheim 21, 5005-5010. doi:10.1002/adma.200901808
36. Faulk, D. M., Londono, R., Wolf, M. T., Ranallo, C. A., Carruthers, C. A., Wildemann, J. D., et al. (2014). ECM hydrogel coating mitigates the chronic inflammatory response to polypropylene mesh. Biomaterials 35, 8585-8595. doi:10.1016/j.biomaterials.2014.06.057
37. FDA. (2014). FDA Approves Orbactiv to Treat Skin Infections. Silver Spring, MD: U.S. Food and Drug Administration.
38. Finetti, F., Basile, A., Capasso, D., Di Gaetano, S., Di Stasi, R., Pascale, M., et al. (2012). Functional and pharmacological characterization of a VEGF mimetic peptide on reparative angiogenesis. Biochem. Pharmacol. 84, 303-311. doi:10.1016/j.bcp.2012.04.011
39. Folkman, J. (2007). Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6, 273-286. doi:10.1038/nrd2115
40. Forsythe, J. A., Jiang, B. H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., et al. (1996). Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16, 4604-4613.
41. Foss, A. C., Goto, T., Morishita, M., and Peppas, N. A. (2004). Development of acrylic-based copolymers for oral insulin delivery. Eur. J. Pharm. Biopharm. 57, 163-169. doi:10.1016/S0939-6411(03)00145-0
42. Frackenpohl, J., Arvidsson, P. I., Schreiber, J. V., and Seebach, D. (2001). The outstanding biological stability of beta-and gamma-peptides toward proteolytic enzymes: an in vitro investigation with fifteen peptidases. Chembiochem 2, 445-455. doi:10.1002/1439-7633(20010601)2:6<445::AID-CBIC445>3.3.CO;2-I
43. Galiano, R. D., Tepper, O. M., Pelo, C. R., Bhatt, K. A., Callaghan, M., Bastidas, N., et al. (2004). Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am. J. Pathol. 164, 1935-1947. doi:10.1016/S0002-9440(10)63754-6
44. Garbern, J. C., Hoffman, A. S., and Stayton, P. S. (2010). Injectable pH-and temperature-responsive poly(N-isopropylacrylamide-co-propylacrylic acid) copolymers for delivery of angiogenic growth factors. Biomacromolecules 11, 1833-1839. doi:10.1021/bm100318z
45. Gentilucci, L., De Marco, R., and Cerisoli, L. (2010). Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr. Pharm. Des. 16, 3185-3203. doi:10.2174/138161210793292555
46. Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., et al. (2014). Heart disease and stroke statistics-2014 update a report from the American heart association. Circulation 129, E28-E292. doi:10.1161/01.cir.0000442015.53336.12
47. Graesslin, O., and Korver, T. (2008). The contraceptive efficacy of implanon: a review of clinical trials and marketing experience. Eur. J. Contracept. Reprod. Health Care 13(Suppl. 1), 4-12. doi:10.1080/13625180801942754
48. Gupta, R., Tongers, J., and Losordo, D. W. (2009). Human studies of angiogenic gene therapy. Circ. Res. 105, 724-736. doi:10.1161/CIRCRESAHA.109.200386
49. Hardy, B., Battler, A., Weiss, C., Kudasi, O., and Raiter, A. (2008). Therapeutic angiogenesis of mouse hind limb ischemia by novel peptide activating GRP78 receptor on endothelial cells. Biochem. Pharmacol. 75, 891-899. doi:10.1016/j.bcp.2007.10.008
50. Hardy, B., Raiter, A., Weiss, C., Kaplan, B., Tenenbaum, A., and Battler, A. (2007). Angiogenesis induced by novel peptides selected from a phage display library by screening human vascular endothelial cells under different physiological conditions. Peptides 28, 691-701. doi:10.1016/j.peptides.2006.11.008
51. Heil, M., Eitenmuller, I., Schmitz-Rixen, T., and Schaper, W. (2006). Arteriogenesis versus angiogenesis: similarities and differences. J. Cell. Mol. Med. 10, 45-55. doi:10.1111/j.1582-4934.2006.tb00290.x
52. Henriksson, M., Nordling, E., Melles, E., Shafqat, J., Stahlberg, M., Ekberg, K., et al. (2005). Separate functional features of proinsulin C-peptide. Cell. Mol. Life Sci. 62, 1772-1778. doi:10.1007/s00018-005-5180-6
53. Henry, T. D., Grines, C. L., Watkins, M. W., Dib, N., Barbeau, G., Moreadith, R., et al. (2007). Effect of Ad5FGF-4 in patients with angina-an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J. Am. Coll. Cardiol. 50, 1038-1046. doi:10.1016/j.jacc.2007.06.010
54. Hern, D. L., and Hubbell, J. A. (1998). Incorporation of adhesion peptides into nonadhesive hydrogels useful for tissue resurfacing. J. Biomed. Mater. Res. 39, 266-276. doi:10.1002/(SICI)1097-4636(199802)39:2<266::AID-JBM14>3.0.CO;2-B
55. Hiemstra, C., Zhong, Z. Y., Van Steenbergen, M. J., Hennink, W. E., and Feijen, J. (2007). Release of model proteins and basic fibroblast growth factor from in situ forming degradable dextran hydrogels. J. Control. Release 122, 71-78. doi:10.1016/j.jconrel.2007.06.011
56. Hirota, K., and Semenza, G. L. (2006). Regulation of angiogenesis by hypoxia-inducible factor 1. Crit. Rev. Oncol. Hematol. 59, 15-26. doi:10.1016/j.critrevonc.2005.12.003
57. Hoffman, M. D., Xie, C., Zhang, X., and Benoit, D. S. (2013). The effect of mesenchymal stem cells delivered via hydrogel-based tissue engineered periosteum on bone allograft healing. Biomaterials 34, 8887-8898. doi:10.1016/j.biomaterials.2013.08.005
58. Hopp, T. P., and Woods, K. R. (1981). Prediction of protein antigenic determinants from amino-acid-sequences. Proc. Natl. Acad. Sci. U.S.A. 78, 3824-3828. doi:10.1073/pnas.78.6.3824
59. Hosack, L. W., Firpo, M. A., Scott, J. A., Prestwich, G. D., and Peattie, R. A. (2008). Microvascular maturity elicited in tissue treated with cytokine-loaded hyaluronan-based hydrogels. Biomaterials 29, 2336-2347. doi:10.1016/j.biomaterials.2008.01.033
60. Hubbell, J. A., Lutolf, M. P., Raeber, G. P., Zisch, A. H., and Tirelli, N. (2003). Cell-responsive synthetic hydrogels. Adv. Mater. Weinheim 15, 888-892. doi:10.1002/adma.200304621
61. Jain, R. A. (2000). The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21, 2475-2490. doi:10.1016/S0142-9612(00)00115-0
62. Jeon, O., Powell, C., Solorio, L. D., Krebs, M. D., and Alsberg, E. (2011). Affinity-based growth factor delivery using biodegradable, photocrosslinked heparin-alginate hydrogels. J. Control. Release 154, 258-266. doi:10.1016/j.jconrel.2011.06.027
63. Jha, A. K., Mathur, A., Svedlund, F. L., Ye, J., Yeghiazarians, Y., and Healy, K. E. (2015). Molecular weight and concentration of heparin in hyaluronic acid-based matrices modulates growth factor retention kinetics and stem cell fate. J. Control. Release 209, 308-316. doi:10.1016/j.jconrel.2015.04.034
64. Jose, S., Hughbanks, M. L., Binder, B. Y., Ingavle, G. C., and Leach, J. K. (2014). Enhanced trophic factor secretion by mesenchymal stem/stromal cells with glycine-histidine-lysine (GHK)-modified alginate hydrogels. Acta Biomater. 10, 1955-1964. doi:10.1016/j.actbio.2014.01.020
65. Kaspar, A. A., and Reichert, J. M. (2013). Future directions for peptide therapeutics development. Drug Discov. Today 18, 807-817. doi:10.1016/j.drudis.2013.05.011
66. Rodgers, K. E., and Dizerega, G. S. Methods for Treating Diabetic Foot Ulcers. USA Patent Application US 13/467,253 (2013).
67. Kent, D. L. (2014). Age-related macular degeneration: beyond anti-angiogenesis. Mol. Vis. 20, 46-55.
68. Kisiday, J., Jin, M., Kurz, B., Hung, H., Semino, C., Zhang, S., et al. (2002). Self-assembling peptide hydrogel fosters chondrocyte extracellular matrix production and cell division: implications for cartilage tissue repair. Proc. Natl. Acad. Sci. U.S.A. 99, 9996-10001. doi:10.1073/pnas.142309999
69. Kleinman, H. K., and Martin, G. R. (2005). Matrigel: basement membrane matrix with biological activity. Semin. Cancer Biol. 15, 378-386. doi:10.1016/j.semcancer.2005.05.004
70. Koczulla, R., Von Degenfeld, G., Kupatt, C., Krotz, F., Zahler, S., Gloe, T., et al. (2003). An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J. Clin. Invest. 111, 1665-1672. doi:10.1172/JCI17545
71. Kuhlmann, C. R., Schaefer, C. A., Reinhold, L., Tillmanns, H., and Erdogan, A. (2005). Signalling mechanisms of SDF-induced endothelial cell proliferation and migration. Biochem. Biophys. Res. Commun. 335, 1107-1114. doi:10.1016/j.bbrc.2005.08.006
72. Laham, R. J., Rezaee, M., Post, M., Sellke, F. W., Braeckman, R. A., Hung, D., et al. (1999). Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. Drug Metab. Dispos. 27, 821-826.
73. Lane, T. F., Iruelaarispe, M. L., Johnson, R. S., and Sage, E. H. (1994). Sparc is a source of copper-binding peptides that stimulate angiogenesis. J. Cell Biol. 125, 929-943. doi:10.1083/jcb.125.4.929
74. Layman, H., Sacasa, M., Murphy, A. E., Murphy, A. M., Pham, S. M., and Andreopoulos, F. M. (2009). Co-delivery of FGF-2 and G-CSF from gelatin-based hydrogels as angiogenic therapy in a murine critical limb ischemic model. Acta Biomater. 5, 230-239. doi:10.1016/j.actbio.2008.07.024
75. Leach, J. B., Bivens, K. A., Patrick, C. W., and Schmidt, C. E. (2003). Photocrosslinked hyaluronic acid hydrogels: natural, biodegradable tissue engineering scaffolds. Biotechnol. Bioeng. 82, 578-589. doi:10.1002/bit.10605
76. Leach, J. B., and Schmidt, C. E. (2005). Characterization of protein release from photocrosslinkable hyaluronic acid-polyethylene glycol hydrogel tissue engineering scaffolds. Biomaterials 26, 125-135. doi:10.1016/j.biomaterials.2004.02.018
77. Lee, T. Y., Folkman, J., and Javaherian, K. (2010). HSPG-binding peptide corresponding to the exon 6a-encoded domain of VEGF inhibits tumor growth by blocking angiogenesis in murine model. PLoS ONE 5:e9945. doi:10.1371/journal.pone.0009945
78. Lehninger, A. L., Nelson, D. L., and Cox, M. M. (2000). Lehninger Principles of Biochemistry. New York, NY: Worth Publishers.
79. Lerman, O. Z., Galiano, R. D., Armour, M., Levine, J. P., and Gurtner, G. C. (2003). Cellular dysfunction in the diabetic fibroblast-impairment in migration, vascular endothelial growth factor production, and response to hypoxia. Am. J. Pathol. 162, 303-312. doi:10.1016/S0002-9440(10)63821-7
80. Liechty, W. B., Kryscio, D. R., Slaughter, B. V., and Peppas, N. A. (2010). Polymers for drug delivery systems. Annu. Rev. Chem. Biomol. Eng. 1, 149-173. doi:10.1146/annurev-chembioeng-073009-100847
81. Lieu, C., Heymach, J., Overman, M., Tran, H., and Kopetz, S. (2011). Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin. Cancer Res. 17, 6130-6139. doi:10.1158/1078-0432.CCR-11-0659
82. Lin, C. C., and Anseth, K. S. (2009a). Controlling affinity binding with peptide-functionalized poly(ethylene glycol) hydrogels. Adv. Funct. Mater. 19, 2325-2331. doi:10.1002/adfm.200900107
83. Lin, C. C., and Anseth, K. S. (2009b). PEG hydrogels for the controlled release of biomolecules in regenerative medicine. Pharm. Res. 26, 631-643. doi:10.1007/s11095-008-9801-2
84. Lin, X. H., Takahashi, K., Liu, Y., Derrien, A., and Zamora, P. O. (2007). A synthetic, bioactive PDGF mimetic with binding to both alpha-PDGF and beta-PDGF receptors. Growth Factors 25, 87-93. doi:10.1080/08977190701553449
85. Lindgren, M., Hallbrink, M., Prochiantz, A., and Langel, U. (2000). Cell-penetrating peptides. Trends Pharmacol. Sci. 21, 99-103. doi:10.1016/S0165-6147(00)01447-4
86. Liu, C. J., Jones, D. S., Tsai, P. C., Venkataramana, A., and Cochran, J. R. (2014). An engineered dimeric fragment of hepatocyte growth factor is a potent c-MET agonist. FEBS Lett. 588, 4831-4837. doi:10.1016/j.febslet.2014.11.018
87. Liu, H., Slamovich, E. B., and Webster, T. J. (2006). Less harmful acidic degradation of poly(lactic-co-glycolic acid) bone tissue engineering scaffolds through titania nanoparticle addition. Int. J. Nanomedicine 1, 541-545. doi:10.2147/nano.2006.1.4.541
88. Liu, J. M., Lawrence, F., Kovacevic, M., Bignon, J., Papadimitriou, E., Lallemand, J. Y., et al. (2003). The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo. Blood 101, 3014-3020. doi:10.1182/blood-2002-07-2315
89. Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., et al. (2010). Heart disease and stroke statistics-2010 update: a report from the American heart association. Circulation 121, e46-e215. doi:10.1161/CIRCULATIONAHA.109.192667
90. Lobmann, R., Ambrosch, A., Schultz, G., Waldmann, K., Schiweck, S., and Lehnert, H. (2002). Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia 45, 1011-1016. doi:10.1007/s00125-002-0868-8
91. Losi, P., Briganti, E., Magera, A., Spiller, D., Ristori, C., Battolla, B., et al. (2010). Tissue response to poly(ether)urethane-polydimethylsiloxane-fibrin composite scaffolds for controlled delivery of pro-angiogenic growth factors. Biomaterials 31, 5336-5344. doi:10.1016/j.biomaterials.2010.03.033
92. Losordo, D. W., and Dimmeler, S. (2004). Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: angiogenic cytokines. Circulation 109, 2487-2491. doi:10.1161/01.CIR.0000128595.79378.FA
93. Lustig, S. R., and Peppas, N. A. (1988). Solute diffusion in swollen membranes.9. Scaling laws for solute diffusion in gels. J. Appl. Polym. Sci. 36, 735-747. doi:10.1002/app.1988.070360401
94. Macchiarini, P., Jungebluth, P., Go, T., Asnaghi, M. A., Rees, L. E., Cogan, T. A., et al. (2008). Clinical transplantation of a tissue-engineered airway. Lancet 372, 2023-2030. doi:10.1016/S0140-6736(08)61598-6
95. Makadia, H. K., and Siegel, S. J. (2011). Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers 3, 1377-1397. doi:10.3390/polym3031377
96. Mandrup-Poulsen, T. (2012). Interleukin-1 antagonists and other cytokine blockade strategies for type 1 diabetes. Rev. Diabet. Stud. 9, 338-347. doi:10.1900/RDS.2012.9.338
97. Maynard, H. D., and Hubbell, J. A. (2005). Discovery of a sulfated tetrapeptide that binds to vascular endothelial growth factor. Acta Biomater. 1, 451-459. doi:10.1016/j.actbio.2005.04.004
98. Montesano, R., Kumar, S., Orci, L., and Pepper, M. S. (1996). Synergistic effect of hyaluronan oligosaccharides and vascular endothelial growth factor on angiogenesis in vitro. Lab. Invest. 75, 249-262.
99. Mooney, D. J., Chen, R. R., Silva, E. A., and Yuen, W. W. (2007). Spatio-temporal VEGF and PDGF delivery patterns blood vessel formation and maturation. Pharm. Res. 24, 258-264. doi:10.1007/s11095-006-9173-4
100. Motamed, K. (1999). SPARC (osteonectin/BM-40). Int. J. Biochem. Cell Biol. 31, 1363-1366. doi:10.1016/S1357-2725(99)00090-4
101. Muir, R. L. (2009). Peripheral arterial disease: pathophysiology, risk factors, diagnosis, treatment, and prevention. J. Vasc. Nurs. 27, 26-30. doi:10.1016/j.jvn.2009.03.001
102. Murry, C. E., Garbern, J. C., Minami, E., and Stayton, P. S. (2011). Delivery of basic fibroblast growth factor with a pH-responsive, injectable hydrogel to improve angiogenesis in infarcted myocardium. Biomaterials 32, 2407-2416. doi:10.1016/j.biomaterials.2010.11.075
103. Nie, T., Baldwin, A., Yamaguchi, N., and Kiick, K. L. (2007). Production of heparin-functionalized hydrogels for the development of responsive and controlled growth factor delivery systems. J. Control. Release 122, 287-296. doi:10.1016/j.jconrel.2007.04.019
104. Niman, H. L., Houghten, R. A., Walker, L. E., Reisfeld, R. A., Wilson, I. A., Hogle, J. M., et al. (1983). Generation of protein-reactive antibodies by short peptides is an event of high-frequency-implications for the structural basis of immune recognition. Proc. Natl. Acad. Sci. U.S.A. 80, 4949-4953. doi:10.1073/pnas.80.16.4949
105. Nishida, N., Yano, H., Nishida, T., Kamura, T., and Kojiro, M. (2006). Angiogenesis in cancer. Vasc. Health Risk Manag. 2, 213-219. doi:10.2147/vhrm.2006.2.3.213
106. Okada, M., Payne, T. R., Oshima, H., Momoi, N., Tobita, K., and Huard, J. (2010). Differential efficacy of gels derived from small intestinal submucosa as an injectable biomaterial for myocardial infarct repair. Biomaterials 31, 7678-7683. doi:10.1016/j.biomaterials.2010.06.056
107. Olsson, A. K., Johansson, I., Akerud, H., Einarsson, B., Christofferson, R., Sasaki, T., et al. (2004). The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization. Cancer Res. 64, 9012-9017. doi:10.1158/0008-5472.CAN-04-2172
108. Ozawa, C. R., Banfi, A., Glazer, N. L., Thurston, G., Springer, M. L., Kraft, P. E., et al. (2004). Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J. Clin. Invest. 113, 516-527. doi:10.1172/JCI18420
109. Papanas, N., and Maltezos, E. (2007). Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises? Int. J. Low. Extrem. Wounds 6, 37-53. doi:10.1177/1534734606298416
110. Patterson, J., and Hubbell, J. A. (2010). Enhanced proteolytic degradation of molecularly engineered PEG hydrogels in response to MMP-1 and MMP-2. Biomaterials 31, 7836-7845. doi:10.1016/j.biomaterials.2010.06.061
111. Peattie, R. A., Nayate, A. P., Firpo, M. A., Shelby, J., Fisher, R. J., and Prestwich, G. D. (2004). Stimulation of in vivo angiogenesis by cytokine-loaded hyaluronic acid hydrogel implants. Biomaterials 25, 2789-2798. doi:10.1016/j.biomaterials.2003.09.054
112. Peattie, R. A., Rieke, E. R., Hewett, E. M., Fisher, R. J., Shu, X. Z., and Prestwich, G. D. (2006). Dual growth factor-induced angiogenesis in vivo using hyaluronan hydrogel implants. Biomaterials 27, 1868-1875. doi:10.1016/j.biomaterials.2005.09.035
113. Peppas, N. A., Hilt, J. Z., Khademhosseini, A., and Langer, R. (2006). Hydrogels in biology and medicine: from molecular principles to bionanotechnology. Adv. Mater. Weinheim 18, 1345-1360. doi:10.1002/adma.200501612
114. Peysselon, F., and Ricard-Blum, S. (2014). Heparin-protein interactions: from affinity and kinetics to biological roles. Application to an interaction network regulating angiogenesis. Matrix Biol. 35, 73-81. doi:10.1016/j.matbio.2013.11.001
115. Phelps, E. A., Landazuri, N., Thule, P. M., Taylor, W. R., and Garcia, A. J. (2010). Bioartificial matrices for therapeutic vascularization. Proc. Natl. Acad. Sci. U.S.A. 107, 3323-3328. doi:10.1073/pnas.0905447107
116. Pickart, L. (2008). The human tri-peptide GHK and tissue remodeling. J. Biomater. Sci. Polym. Ed. 19, 969-988. doi:10.1163/156856208784909435
117. Pike, D. B., Cai, S. S., Pomraning, K. R., Firpo, M. A., Fisher, R. J., Shu, X. Z., et al. (2006). Heparin-regulated release of growth factors in vitro and angiogenic response in vivo to implanted hyaluronan hydrogels containing VEGF and bFGF. Biomaterials 27, 5242-5251. doi:10.1016/j.biomaterials.2006.05.018
118. Plunkett, M. L., Tel-Tsur, Z., Bera, M., Beck, I., Avery, J., Livant, D. L., et al. (2002). A novel anti-angiogenic/anti-metastatic peptide, ATN-161 (Ac-PHSCN-NH2), which targets multiple fully activated integrins including alpha-5 beta-1 and alpha-v beta-3, leads to increased anti-tumor activity and increased survival in multiple tumor models when combined with chemotherapy. Eur. J. Cancer 38, S79. doi:10.1016/S0959-8049(02)80901-7
119. Porter, S. (2001). Human immune response to recombinant human proteins. J. Pharm. Sci. 90, 1-11. doi:10.1002/1520-6017(200101)90:1<1::AID-JPS1>3.0.CO;2-K
120. Radius Health, I. (2015). Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women (ACTIVE). Available from: ClinicalTrials.gov.
121. Raya-Rivera, A., Esquiliano, D. R., Yoo, J. J., Lopez-Bayghen, E., Soker, S., and Atala, A. (2011). Tissue-engineered autologous urethras for patients who need reconstruction: an observational study. Lancet 377, 1175-1182. doi:10.1016/S0140-6736(10)62354-9
122. Renukuntla, J., Vadlapudi, A. D., Patel, A., Boddu, S. H. S., and Mitra, A. K. (2013). Approaches for enhancing oral bioavailability of peptides and proteins. Int. J. Pharm. 447, 75-93. doi:10.1016/j.ijpharm.2013.02.030
123. Richardson, T. P., Peters, M. C., Ennett, A. B., and Mooney, D. J. (2001). Polymeric system for dual growth factor delivery. Nat. Biotechnol. 19, 1029-1034. doi:10.1038/nbt1101-1029
124. Riley, C. M., Fuegy, P. W., Firpo, M. A., Shu, X. Z., Prestwich, G. D., and Peattie, R. A. (2006). Stimulation of in vivo angiogenesis using dual growth factor-loaded crosslinked glycosaminoglycan hydrogels. Biomaterials 27, 5935-5943. doi:10.1016/j.biomaterials.2006.08.029
125. Rodell, C. B., Kaminski, A. L., and Burdick, J. A. (2013). Rational design of network properties in guest-host assembled and shear-thinning hyaluronic acid hydrogels. Biomacromolecules 14, 4125-4134. doi:10.1021/bm401280z
126. Rodell, C. B., Wade, R. J., Purcell, B. P., Dusaj, N. N., and Burdick, J. A. (2015). Selective proteolytic degradation of guest-host assembled, injectable hyaluronic acid hydrogels. ACS Biomater. Sci. Eng. 1, 277-286. doi:10.1021/ab5001673
127. Rozek, A., Powers, J. P. S., Friedrich, C. L., and Hancock, R. E. W. (2003). Structure-based design of an indolicidin peptide analogue with increased protease stability. Biochemistry 42, 14130-14138. doi:10.1021/bi035643g
128. Rustad, K. C., Wong, V. W., Sorkin, M., Glotzbach, J. P., Major, M. R., Rajadas, J., et al. (2012). Enhancement of mesenchymal stem cell angiogenic capacity and stemness by a biomimetic hydrogel scaffold. Biomaterials 33, 80-90. doi:10.1016/j.biomaterials.2011.09.041
129. Sakiyama-Elbert, S. E., and Hubbell, J. A. (2000a). Controlled release of nerve growth factor from a heparin-containing fibrin-based cell ingrowth matrix. J. Control. Release 69, 149-158. doi:10.1016/S0168-3659(00)00296-0
130. Sakiyama-Elbert, S. E., and Hubbell, J. A. (2000b). Development of fibrin derivatives for controlled release of heparin-binding growth factors. J. Control. Release 65, 389-402. doi:10.1016/S0168-3659(99)00221-7
131. Santulli, G., Ciccarelli, M., Palumbo, G., Campanile, A., Galasso, G., Ziaco, B., et al. (2009). In vivo properties of the proangiogenic peptide QK. J. Transl. Med. 7, 41. doi:10.1186/1479-5876-7-41
132. Sarmento, B., Ferreira, D. C., Jorgensen, L., and Van De Weert, M. (2007). Probing insulin's secondary structure after entrapment into alginate/chitosan nanoparticles. Eur. J. Pharm. Biopharm. 65, 10-17. doi:10.1016/j.ejpb.2006.09.005
133. Schmoekel, H. G., Weber, F. E., Schense, J. C., Gratz, K. W., Schawalder, P., and Hubbell, J. A. (2005). Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices. Biotechnol. Bioeng. 89, 253-262. doi:10.1002/bit.20168
134. Schultz, P., Vautier, D., Richert, L., Jessel, N., Haikel, Y., Schaaf, P., et al. (2005). Polyelectrolyte multilayers functionalized by a synthetic analogue of an anti-inflammatory peptide, alpha-MSH, for coating a tracheal prosthesis. Biomaterials 26, 2621-2630. doi:10.1016/j.biomaterials.2004.06.049
135. Segal, E., and Satchi-Fainaro, R. (2009). Design and development of polymer conjugates as anti-angiogenic agents. Adv. Drug Deliv. Rev. 61, 1159-1176. doi:10.1016/j.addr.2009.06.005
136. Seif-Naraghi, S. B., Horn, D., Schup-Magoffin, P. J., and Christman, K. L. (2012). Injectable extracellular matrix derived hydrogel provides a platform for enhanced retention and delivery of a heparin-binding growth factor. Acta Biomater. 8, 3695-3703. doi:10.1016/j.actbio.2012.06.030
137. Selivanova, G., Iotsova, V., Okan, I., Fritsche, M., Strom, M., Groner, B., et al. (1997). Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med. 3, 632-638. doi:10.1038/nm0697-632
138. Shih, H., and Lin, C. C. (2012). Cross-linking and degradation of step-growth hydrogels formed by thiol-ene photoclick chemistry. Biomacromolecules 13, 2003-2012. doi:10.1021/bm300752j
139. Shoyele, S. A., and Cawthorne, S. (2006). Particle engineering techniques for inhaled biopharmaceuticals. Adv. Drug Deliv. Rev. 58, 1009-1029. doi:10.1016/j.addr.2006.07.010
140. Silva, E. A., and Mooney, D. J. (2007). Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis. J. Thromb. Haemost. 5, 590-598. doi:10.1111/j.1538-7836.2007.02386.x
141. Silva, E. A., and Mooney, D. J. (2010). Effects of VEGF temporal and spatial presentation on angiogenesis. Biomaterials 31, 1235-1241. doi:10.1016/j.biomaterials.2009.10.052
142. Singelyn, J. M., Sundaramurthy, P., Johnson, T. D., Schup-Magoffin, P. J., Hu, D. P., Faulk, D. M., et al. (2012). Catheter-deliverable hydrogel derived from decellularized ventricular extracellular matrix increases endogenous cardiomyocytes and preserves cardiac function post-myocardial infarction. J. Am. Coll. Cardiol. 59, 751-763. doi:10.1016/j.jacc.2011.10.888
143. Slaughter, B. V., Khurshid, S. S., Fisher, O. Z., Khademhosseini, A., and Peppas, N. A. (2009). Hydrogels in regenerative medicine. Adv. Mater. Weinheim 21, 3307-3329. doi:10.1002/adma.200802106
144. Slyke, P.V. Multimeric TIE 2 Agonists and Uses Thereof in Stimulating Angiogenesis. USA Patent Application 12/446,511 (2011).
145. Soldani, G., Losi, P., Bernabei, M., Burchielli, S., Chiappino, D., Kull, S., et al. (2010). Long term performance of small-diameter vascular grafts made of a poly(ether)urethane-polydimethylsiloxane semi-interpenetrating polymeric network. Biomaterials 31, 2592-2605. doi:10.1016/j.biomaterials.2009.12.017
146. Sonnenberg, S. B., Rane, A. A., Liu, C. J., Rao, N., Agmon, G., Suarez, S., et al. (2015). Delivery of an engineered HGF fragment in an extracellular matrix-derived hydrogel prevents negative LV remodeling post-myocardial infarction. Biomaterials 45, 56-63. doi:10.1016/j.biomaterials.2014.12.021
147. Soro, S., Orecchia, A., Morbidelli, L., Lacal, P. M., Morea, V., Ballmer-Hofer, K., et al. (2008). A proangiogenic peptide derived from vascular endothelial growth factor receptor-1 acts through alpha 5 beta 1 integrin. Blood 111, 3479-3488. doi:10.1182/blood-2007-03-077537
148. Steed, D. L. (1995). Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic ulcer study group. J. Vasc. Surg. 21, 71-78. doi:10.1016/S0741-5214(95)70245-8
149. Stern, R. (2004). Hyaluronan catabolism: a new metabolic pathway. Eur. J. Cell Biol. 83, 317-325. doi:10.1078/0171-9335-00392
150. Struman, I., Bentzien, F., Lee, H. Y., Mainfroid, V., D'Angelo, G., Goffin, V., et al. (1999). Opposing actions of intact and N-terminal fragments of the human prolactin growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 96, 1246-1251. doi:10.1073/pnas.96.4.1246
151. Sun, Q. H., Chen, R. R., Shen, Y. C., Mooney, D. J., Rajagopalan, S., and Grossman, P. M. (2005). Sustained vascular endothelial growth factor delivery enhances angiogenesis and perfusion in ischemic hind limb. Pharm. Res. 22, 1110-1116. doi:10.1007/s11095-005-5644-2
152. Sylven, C., Hao, X. J., Silva, E. A., Mansson-Broberg, A., Grinnemo, K. H., Siddiqui, A. J., et al. (2007). Angiogenic effects of sequential release of VEGF-A(165) and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc. Res. 75, 178-185. doi:10.1016/j.cardiores.2007.03.028
153. Tabata, Y., and Ikada, Y. (1998). Protein release from gelatin matrices. Adv. Drug Deliv. Rev. 31, 287-301. doi:10.1016/S0169-409X(97)00125-7
154. Tae, G., Scatena, M., Stayton, P. S., and Hoffman, A. S. (2006). PEG-cross-linked heparin is an affinity hydrogel for sustained release of vascular endothelial growth factor. J. Biomater. Sci. Polym. Ed. 17, 187-197. doi:10.1163/156856206774879090
155. Thomas, U., Themis, K., Filippo, G. M., Carlo Alberto, O., Dave, H., Diederik, H., et al. (2014). The emergence of peptides in the pharmaceutical business: from exploration to exploitation. EuPA Open Proteom. 4, 58-69. doi:10.1016/j.euprot.2014.05.003
156. Tiwari, G., Tiwari, R., and Rai, A. K. (2010). Cyclodextrins in delivery systems: applications. J. Pharm. Bioallied Sci. 2, 72-79. doi:10.4103/0975-7406.67003
157. Turco, G., Donati, I., Grassi, M., Marchioli, G., Lapasin, R., and Paoletti, S. (2011). Mechanical spectroscopy and relaxometry on alginate hydrogels: a comparative analysis for structural characterization and network mesh size determination. Biomacromolecules 12, 1272-1282. doi:10.1021/bm101556m
158. van de Wetering, P., Metters, A. T., Schoenmakers, R. G., and Hubbell, J. A. (2005). Poly(ethylene glycol) hydrogels formed by conjugate addition with controllable swelling, degradation, and release of pharmaceutically active proteins. J. Control. Release 102, 619-627. doi:10.1016/j.jconrel.2004.10.029
159. Van Hove, A. H., Beltejar, M. J., and Benoit, D. S. (2014). Development and in vitro assessment of enzymatically responsive poly(ethylene glycol) hydrogels for the delivery of therapeutic peptides. Biomaterials 35, 9719-9730. doi:10.1016/j.biomaterials.2014.08.019
160. Van Hove, A. H., Willson, B., and Benoit, D. S. (2013). Microwave-assisted functionalization of poly(ethylene glycol) and on-resin peptides for use in chain polymerizations and hydrogel formation. J. Vis. Exp. 80, e50890. doi:10.3791/50890
161. Van Slyke, P., Alami, J., Martin, D., Kuliszewski, M., Leong-Poi, H., Sefton, M. V., et al. (2009). Acceleration of diabetic wound healing by an angiopoietin peptide mimetic. Tissue Eng. Part A 15, 1269-1280. doi:10.1089/ten.tea.2007.0400
162. Vasudev, N. S., and Reynolds, A. R. (2014). Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 17, 471-494. doi:10.1007/s10456-014-9420-y
163. Verrecchio, A., Germann, M. W., Schick, B. P., Kung, B., Twardowski, T., and San Antonio, J. D. (2000). Design of peptides with high affinities for heparin and endothelial cell proteoglycans. J. Biol. Chem. 275, 7701-7707. doi:10.1074/jbc.275.11.7701
164. Vinoth Prabhu, V., Chidambaranathan, N., and Gopal, V. (2011). A historical review on current medication and therapies for inducing and inhibiting angiogenesis. J. Chem. Pharm. Res. 3, 526-533.
165. Vlieghe, P., Lisowski, V., Martinez, J., and Khrestchatisky, M. (2010). Synthetic therapeutic peptides: science and market. Drug Discov. Today 15, 40-56. doi:10.1016/j.drudis.2009.10.009
166. Welti, J., Loges, S., Dimmeler, S., and Carmeliet, P. (2013). Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J. Clin. Invest. 123, 3190-3200. doi:10.1172/JCI70212
167. West, J. L., and Hubbell, J. A. (1999). Polymeric biomaterials with degradation sites for proteases involved in cell migration. Macromolecules 32, 241-244. doi:10.1021/ma981296k
168. Wieghaus, K. A., Nickerson, M. M., Petrie Aronin, C. E., Sefcik, L. S., Price, R. J., Paige, M. A., et al. (2008). Expansion of microvascular networks in vivo by phthalimide neovascular factor 1 (PNF1). Biomaterials 29, 4698-4708. doi:10.1016/j.biomaterials.2008.08.029
169. Willerth, S. M., Johnson, P. J., Maxwell, D. J., Parsons, S. R., Doukas, M. E., and Sakiyama-Elbert, S. E. (2007). Rationally designed peptides for controlled release of nerve growth factor from fibrin matrices. J. Biomed. Mater. Res. A. 80A, 13-23. doi:10.1002/jbm.a.30844
170. Yamamoto, M., Ikada, Y., and Tabata, Y. (2001). Controlled release of growth factors based on biodegradation of gelatin hydrogel. J. Biomater. Sci. Polym. Ed. 12, 77-88. doi:10.1163/156856201744461
171. Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., and Holash, J. (2000). Vascular-specific growth factors and blood vessel formation. Nature 407, 242-248. doi:10.1038/35025215
172. Yang, L. L., Mashima, T., Sato, S., Mochizuki, M., Sakamoto, H., Yamori, T., et al. (2003). Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res. 63, 831-837.
173. Ye, Q., Zund, G., Benedikt, P., Jockenhoevel, S., Hoerstrup, S. P., Sakyama, S., et al. (2000). Fibrin gel as a three dimensional matrix in cardiovascular tissue engineering. Eur. J. Cardiothorac. Surg. 17, 587-591. doi:10.1016/S1010-7940(00)00373-0
174. Young, S., Wong, M., Tabata, Y., and Mikos, A. G. (2005). Gelatin as a delivery vehicle for the controlled release of bioactive molecules. J. Control. Release 109, 256-274. doi:10.1016/j.jconrel.2005.09.023
175. Zachary, I., and Morgan, R. D. (2011). Therapeutic angiogenesis for cardiovascular disease: biological context, challenges, prospects. Heart 97, 181-189. doi:10.1136/hrt.2009.180414
176. Zhanel, G. G., Schweizer, F., and Karlowsky, J. A. (2012). Oritavancin: mechanism of action. Clin. Infect. Dis. 54(Suppl. 3), S214-S219. doi:10.1093/cid/cir920
177. Ziche, M., Donnini, S., and Morbidelli, L. (2004). Development of new drugs in angiogenesis. Curr. Drug Targets 5, 485-493. doi:10.2174/1389450043345371
178. Zisch, A. H., Lutolf, M. P., Ehrbar, M., Raeber, G. P., Rizzi, S. C., Davies, N., et al. (2003). Cell-demanded release of VEGF from synthetic, biointeractive cell-ingrowth matrices for vascularized tissue growth. FASEB J. 17, 2260-2262. doi:10.1096/fj.02-1041fje
179. Zisch, A. H., Schenk, U., Schense, J. C., Sakiyama-Elbert, S. E., and Hubbell, J. A. (2001). Covalently conjugated VEGF-fibrin matrices for endothelialization. J. Control. Release 72, 101-113. doi:10.1016/S0168-3659(01)00266-8